Comment
doi: 10.1136/annrheumdis-2020-218075.
Epub 2020 Jun 26.
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Affiliations
- PMID: 32591357
- DOI: 10.1136/annrheumdis-2020-218075
Item in Clipboard
Comment
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Ann Rheum Dis.
2021 May.
No abstract available
Keywords: B-Lymphocytes; arthritis, rheumatoid; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591359 No abstract available.
Comment on
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive _targeted therapies.Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2. Ann Rheum Dis. 2020. PMID: 32241793 Free PMC article. No abstract available.
Similar articles
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591359 No abstract available.
-
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.Immunol Res. 2021 Aug;69(4):309-311. doi: 10.1007/s12026-021-09212-5. Epub 2021 Jul 29. Immunol Res. 2021. PMID: 34324159 Free PMC article. No abstract available.
-
Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy.J Infect Dis. 2021 Aug 2;224(3):557-559. doi: 10.1093/infdis/jiab248. J Infect Dis. 2021. PMID: 33964153 Free PMC article. No abstract available.
-
Efficacy and safety of rituximab in rheumatic diseases.Wien Med Wochenschr. 2015 Jan;165(1-2):28-35. doi: 10.1007/s10354-014-0331-8. Epub 2015 Jan 21. Wien Med Wochenschr. 2015. PMID: 25676699 Review.
-
Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies.Rev Bras Reumatol Engl Ed. 2016 Nov-Dec;56(6):543-550. doi: 10.1016/j.rbre.2016.10.001. Epub 2016 Oct 27. Rev Bras Reumatol Engl Ed. 2016. PMID: 27914602 Review. English, Portuguese.
Cited by
-
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).Vaccines (Basel). 2024 Oct 11;12(10):1157. doi: 10.3390/vaccines12101157. Vaccines (Basel). 2024. PMID: 39460324 Free PMC article.
-
The impact of COVID-19 pandemic on patients with ANCA associated vasculitis.J Nephrol. 2021 Feb;34(1):185-190. doi: 10.1007/s40620-020-00881-3. Epub 2020 Oct 8. J Nephrol. 2021. PMID: 33034038 Free PMC article.
-
Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review.Vaccines (Basel). 2022 Feb 15;10(2):297. doi: 10.3390/vaccines10020297. Vaccines (Basel). 2022. PMID: 35214755 Free PMC article. Review.
-
Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies.J Res Med Sci. 2021 Sep 30;26:85. doi: 10.4103/jrms.JRMS_1047_20. eCollection 2021. J Res Med Sci. 2021. PMID: 34760002 Free PMC article.
-
How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.Front Immunol. 2021 Jun 11;12:646894. doi: 10.3389/fimmu.2021.646894. eCollection 2021. Front Immunol. 2021. PMID: 34177895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
